Two abstracts were presented recently, with one reporting no change in liver chemistry, whereas the second abstract observed an increasing trend of serum alkaline phosphatase at the 30‐week follow up. 22 , 23 Safety A recent systematic review of vedolizumab‐exposed patients from six registration trials (2830 patients) and six postmarketing cohort studies (1049 patients) demonstrated no increase in adverse events (AE) or serious adverse events (SAE) in the vedolizumab‐exposed group. 24 Follow up ranged from 10 weeks to 46 months for the registration trials and 14 to 53 weeks for the cohort studies.
← all excerpts
A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.
1
—
—